(CercleFinance.com) – The group announces that the phase IIb data on amlitelimab presented at the EADV Congress illustrate its profile as a potential best-in-class drug for the treatment of atopic dermatitis.
The mean Eczema Area and Severity Index (EASI) score of patients treated with amlitelimab decreased by up to 61.5% at week 16 compared to baseline. (primary endpoint); this score continued to decline until week 24.
Clinically meaningful improvements were also observed at week 16 for key secondary endpoints and continued through week 24.
Professor Stephan Weidinger, MD, Ph.D. Director, Professor, Director of the Department of Dermatology and Allergology at the University Hospital of Schleswig-Holstein said ‘At all four doses studied, we observed convergent improvements in the main signs and disease symptoms, with a favorable safety profile. ‘